HYDERABAD: Dr Reddy's Laboratories has launched in the US market ropinirole hydrochloride XR (extended release) tablets used to treat the signs and symptoms of Parkinson's disease.
Ropinirole hydrochloride XR tablets are the bioequivalent generic version of Requip XL tablets, a registered trademark of pharma giant SmithKline Beecham.
The Indian company has obtained the approval of the United States Food and Drug Administration for its abbreviated new drug application for ropinirole hydrochloride XR tablets to launch a generic product. Requip XL had reported sales of around $58 million for the 12 months period ended March 2012 in the US market according to IMS Health.
Dr Reddy's said its ropinirole hydrochloride XR tablets in 2 mg, 4 mg and 6 mg will be available in 30 and 90 count bottle sizes, 8 mg and 12 mg in 30 count bottle sizes.
Ropinirole hydrochloride XR tablets are the bioequivalent generic version of Requip XL tablets, a registered trademark of pharma giant SmithKline Beecham.
The Indian company has obtained the approval of the United States Food and Drug Administration for its abbreviated new drug application for ropinirole hydrochloride XR tablets to launch a generic product. Requip XL had reported sales of around $58 million for the 12 months period ended March 2012 in the US market according to IMS Health.
Dr Reddy's said its ropinirole hydrochloride XR tablets in 2 mg, 4 mg and 6 mg will be available in 30 and 90 count bottle sizes, 8 mg and 12 mg in 30 count bottle sizes.
